LONDON, July 26 /PRNewswire/ -- Heightened awareness and knowledge about diabetes are boosting the acceptance of insulin therapy among people with type 2 diabetes. This, together with the emergence of innovative and effective diabetes management solutions, will act as a major driver for the insulin market over the coming years.
Frost & Sullivan (http://www.healthcare.frost.com) finds that the European Diabetes Market will earn revenues of $2.80 billion in 2005 and estimates this to reach $4.60 billion in 2012.
"Technological advancements in the field of drug delivery have propelled scientists to research new and more convenient forms of insulin delivery," notes Frost & Sullivan Research Analyst Sylvia Miriyam Findlay. "The subsequent emergence of newer methods of insulin delivery including inhaled insulin, oral insulin, transdermal insulin will eventually expand the insulin market."
At present, the insulin market is at a growth stage, while the oral anti-diabetic market is in the mature phase. Despite cost barriers, nascent non-invasive insulin delivery technologies are set to stimulate overall market growth. Novel oral drugs such as the dual PPAR agonists, currently in the pipeline, are poised to gain market share due their efficacy.
Reimbursement limitations are currently restraining the uptake of these newer and more expensive forms of insulin. For instance, inhaled insulin and oral insulin are typically costlier than standard insulin vials and cartridges. With reimbursement for insulin devices and novel forms of insulin still uncertain, the penetration of such novel insulin delivery forms across the European Union will constitute a difficult task.
"Pharmaceutical companies need to work towards empowering diabetic patients to more effectively self-manage their condition," advises Ms. Findlay. "They need to aggressively provide value-added services to enhance product differentiation, while promoting end-user familiarity with products."
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the European Diabetes Market (B935-52) then send an e-mail to Radhika Menon Theodore- Corporate Communications at rmtheodore@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.
European Diabetes Market is part of the Pharmaceutical and Clinical Diagnostics Subscription, which also includes research in the following markets: Diabetes Drug Delivery Methods - Market and Technologies, European Central Nervous System Markets and, European Anti-Depressants Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.
Contact: Radhika Menon Theodore Corporate Communications - Europe P: +91-44-42044541 F: +91-44-24314264 E: rmtheodore@frost.com Melina Trevino Corporate Communications - Americas P: +1-210-247-2440 F: +1-210-348-1003 E: melina.trevino@frost.com Surbhi Dedhia Corporate Communications - India P: +91-22-5001-3431 E: sdedhia@frost.com Jasminder Kaur Corporate Communications - Asia Pacific P: +65-68900937 E: jkaur@frost.com Sharmin Jassal Corporate Communications - Australia P: +61-2-8247-8900 F: +61-2-9252 -8066 E: sjassal@frost.comwww.frost.com
Keywords in this release: diabetes, diabetes management, European markets, insulin therapy, Type 2 diabetes, drug delivery, insulin delivery, inhaler insulin, oral insulin, transdermal insulin, islet cell transplantation, oral anti-diabetic market, non-invasive insulin delivery technologies, dual PPAR agonists, standard insulin vials, insulin cartridges
Frost & SullivanCONTACT: Contact: Radhika Menon Theodore, Corporate Communications -Europe, P: +91-44-42044541, F: +91-44-24314264, E: rmtheodore@frost.com.Melina Trevino, Corporate Communications - Americas, P: +1-210-247-2440, F:+1-210-348-1003, E: melina.trevino@frost.com. Surbhi Dedhia, CorporateCommunications - India, P: +91-22-5001-3431, E: sdedhia@frost.com.Jasminder Kaur, Corporate Communications - Asia Pacific, P: +65-68900937,E: jkaur@frost.com. Sharmin Jassal, Corporate Communications - Australia,P: +61-2-8247-8900, F: +61-2-9252 -8066, E: sjassal@frost.com
